Executives Depart Cassava, Maker of Disputed Alzheimer’s Drug

Health
By Teddy Rosenbluth from NYT Health https://ift.tt/xgpP6fk
via IFTTT your-feed-science, Appointments and Executive Changes, Drugs (Pharmaceuticals), Clinical Trials, Alzheimer's Disease, Falsification of Data, Research, Academic and Scientific Journals, Securities and Commodities Violations The chief executive and a lead scientist stepped down weeks after a federal grand jury filed fraud charges against a research collaborator.

Comments

Popular posts from this blog

U.S. Quietly Drafts Plan to End Program That Saved Millions From AIDS

The Jarring Contradiction at the Heart of Kennedy’s Agenda